Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
Brief Summary: The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer


Options:
A: Arm Label: LY2157299 monohydrate plus lomustine; Type: EXPERIMENTAL; Interventions: Drug: LY2157299 monohydrate, Drug: Lomustine | Arm Label: LY2157299 monohydrate; Type: EXPERIMENTAL; Interventions: Drug: LY2157299 monohydrate | Arm Label: lomustine plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine, Drug: Placebo | Intervention Type: DRUG; Name: LY2157299 monohydrate; Assigned to Arm(s): LY2157299 monohydrate, LY2157299 monohydrate plus lomustine | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): LY2157299 monohydrate plus lomustine, lomustine plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lomustine plus placebo
B: Arm Label: First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Lomustine, Radiation: Radiotherapy, Drug: Temozolomide, Drug: SOC Agent | Arm Label: First-Line Bevacizumab followed by Placebo + Lomustine/SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Lomustine, Drug: Placebo, Radiation: Radiotherapy, Drug: Temozolomide, Drug: SOC Agent | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC | Intervention Type: DRUG; Name: SOC Agent; Assigned to Arm(s): First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC, First-Line Bevacizumab followed by Placebo + Lomustine/SOC
C: Arm Label: ADV-TK/GCV; Type: EXPERIMENTAL; Interventions: Biological: ADV-TK/GCV | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: systemic chemotherapy | Intervention Type: BIOLOGICAL; Name: ADV-TK/GCV; Assigned to Arm(s): ADV-TK/GCV | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Control group | Intervention Type: DRUG; Name: systemic chemotherapy; Assigned to Arm(s): Control group
D: Arm Label: Arm A: SRT to the resection cavity; Type: EXPERIMENTAL; Interventions: Radiation: SRT to the resection cavity | Arm Label: Arm B: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: RADIATION; Name: SRT to the resection cavity; Assigned to Arm(s): Arm A: SRT to the resection cavity

Answer: A